Again good news from Acarix

Today, Acarix has announced that yet another payer has granted USD 300 in fixed reimbursement for use of the CADScor test. As fixed reimbursement in our view is of major importance for parts of the US business case, it is encouraging to see that a dedicated effort and long-term work now is yielding results. 

Due to our CEO Jan Poulsen being the chairman of the board in Acarix, we refrain from commenting further on this news but refer to the company's press release here.